Ranok: a chaperone-based approach to targeted degradation

An investor syndicate is backing Chinese biotech Ranok in a $40 million series B round that will allow the targeted protein degradation company to test its differentiated, chaperone-based approach in its first clinical trial.

Hangzhou-based Ranok Therapeutics Co. Ltd. is deepening its presence in the U.S. as it is poised to enter the clinic, founder and CEO Weiwen Ying told BioCentury. The biotech is preparing to conduct its first clinical trial in the U.S., and has a beachhead in Boston...